Volume 84 - 2021 - Fasc.2 - Expert Point of View
Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC)
Liver transplantation (LT) remains the only curative option
for patients suffering from end-stage liver disease, acute liver
failure and selected hepatocellular carcinomas and access to the
LT-waiting list is limited to certain strict indications. However, LT
has shown survival advantages for patients in certain indications
such as acute alcoholic hepatitis, hepatocellular carcinoma outside
Milan criteria and colorectal cancer metastases. These newer
indications increase the pressure in an already difficult context of
organ shortage. Strategies to increase the transplantable organ pool
are therefore needed. We will discuss here the use of HCV positive
grafts as the use of normothermic isolated liver perfusion. Belgian
Liver Intestine Advisory Committee (BeLIAC) from the Belgian
Transplant Society (BTS) aims to guarantee the balance between
the new indications and the available resources.
